CBLN4 Antibody

What are the optimal applications and dilutions for CBLN4 antibodies?

CBLN4 antibodies have been validated for multiple research applications, though optimal dilutions vary by application and specific antibody:

For optimal results, titration experiments should be performed with each new antibody lot using appropriate positive control tissues (mouse cerebellum, brain, and kidney tissues are recommended positive controls) .

What tissue expression pattern should I expect when using CBLN4 antibodies?

CBLN4 expression has been confirmed in several tissues with distinct staining patterns:

Additionally, CBLN4 has been detected in select neurons in the dorsal raphe, entorhinal cortex, and arcuate nucleus . When conducting comparative studies, include appropriate negative controls, including tissue from CBLN4-null mice when available.

How should I store and handle CBLN4 antibodies for optimal stability?

To maintain antibody integrity and performance:

• Store at -20°C for long-term (up to 12 months from receipt)

• For frequent use, store at 4°C for up to one month

• Avoid repeated freeze-thaw cycles (aliquot upon first thaw)

• Most formulations contain PBS with 0.02% sodium azide and 50% glycerol, pH 7.3

• 20μl sizes typically contain 0.1% BSA

• Allow antibody to reach room temperature before opening

The stability data shows antibodies remain functionally active for at least 12 months when stored properly, with reconstituted antibodies maintaining activity for 6 months at -20°C to -70°C .

How can I validate the specificity of my CBLN4 antibody?

Comprehensive validation requires multiple approaches:

• Western blot validation:

  • Use known positive tissues (mouse cerebellum, brain)

  • Include negative controls (if available, CBLN4-knockout tissue)

  • Perform peptide competition assays using the immunizing peptide

  • Expected molecular weight: 22 kDa

• Cross-reactivity assessment:

  • Some CBLN4 antibodies (e.g., 20559-1-AP) are documented to have no cross-reaction to CBLN1, 2, or 3

  • Other antibodies may cross-react with Cbln1, requiring careful control design

  • Use Cbln1-null mice tissues as controls when possible to distinguish genuine CBLN4 staining

• Immunohistochemistry validation:

  • Compare staining patterns with published expression data

  • Include known positive (cerebellum) and negative tissues

  • Conduct parallel staining with two different CBLN4 antibodies raised against different epitopes

What antigen retrieval methods are optimal for CBLN4 immunohistochemistry?

Successful IHC for CBLN4 requires careful antigen retrieval optimization:

For paraffin-embedded sections, heat-induced epitope retrieval is essential. After retrieval, optimal staining can be achieved by incubating sections with antibody dilutions of 1:50-1:200, followed by appropriate detection systems (e.g., Anti-Sheep HRP-DAB for R&D Systems' antibody AF6740) .

How can I distinguish between homometric and heteromeric CBLN4 complexes?

CBLN4 has unique multimerization properties that require specialized approaches:

• Biochemical analysis:

  • Native PAGE combined with Western blotting can distinguish different complex sizes

  • Mature CBLN4 contains two N-terminal cysteines mediating homohexamer formation

  • The C-terminal C1q domain (aa 66-201) promotes homotrimer formation

  • Gradient gels (4-15%) provide better resolution of different complex sizes

• Co-immunoprecipitation studies:

  • CBLN4 forms complexes with other CBLN-related molecules (CBLN1-3)

  • Complexes containing both CBLN1 and CBLN4 show reduced affinity to DCC but increased affinity to Neurexins

  • Use antibodies specific to different CBLN family members for co-IP studies

• Functional discrimination:

  • Heteromeric complexes demonstrate different binding properties than homomeric ones

  • CBLN4 can enable ER export and secretion of CBLN3

What experimental approaches best characterize CBLN4's role in neuronal signaling pathways?

To investigate CBLN4's signaling roles:

• Receptor binding studies:

  • Unlike CBLN1 and CBLN2 (which bind to GluRδ2 and Nrxns1-3), CBLN4 binds weakly or not at all to these receptors

  • CBLN4 selectively binds to the netrin receptor DCC (deleted in colorectal cancer) in a netrin-displaceable fashion

  • Use netrin competition assays to verify binding specificity

• Knockout model analysis:

  • CBLN4-null mice provide critical insights but do not phenocopy netrin-null mice

  • CBLN4-null mice lack the striatal synaptic changes seen in CBLN1-null mice

  • Use comparative morphological and electrophysiological measures across these models

• Co-localization studies:

  • CBLN1 and CBLN4 are co-localized in neurons responsible for synaptic changes in striatum

  • Use dual immunofluorescence with confocal microscopy for precise localization

  • Include subcellular markers like cathepsin D (lysosome marker) to establish compartmentalization

What are the common issues with CBLN4 antibody staining and how can they be addressed?

Quality control measures should include parallel staining of known positive tissues (cerebellum, hypothalamus) and verification with multiple antibodies when possible .

How can I adapt protocols for detecting CBLN4 in different experimental systems?

For specialized research applications:

• Primary neuron cultures:

  • Immunocytochemistry: Fix in 4% PFA for 15 minutes at RT

  • Permeabilize with 0.1% Triton X-100 for 10 minutes

  • Use antibody at 1:100-1:200 dilutions for optimal detection

  • Co-stain with neuronal markers (MAP2, NeuN) for better localization

• Brain slice preparations:

  • Free-floating sections (40μm): Increase antibody concentration

  • Thick sections may require longer incubation times (48-72 hours)

  • Consider using tissue clearing techniques for better penetration

• Non-CNS tissues:

  • Testis: Requires special fixation (Bouin's solution improves results)

  • Kidney: Increase antibody concentration (1:100-1:200)

  • Positive staining in these tissues helps confirm antibody functionality

What considerations are important when using CBLN4 antibodies for subcellular localization studies?

For accurate subcellular localization:

• Confocal microscopy optimization:

  • Use antibodies validated for immunofluorescence

  • Co-stain with established subcellular markers:

    • Cathepsin D for lysosomes (important CBLN4 co-localization)

    • Calnexin/PDI for ER (where CBLN4 enables CBLN3 export)

    • TGN46 for trans-Golgi network

• Sample preparation:

  • Heat-mediated antigen retrieval on paraffin sections

  • Incubate overnight with rabbit anti-CBLN4 (1:300) and goat anti-cathepsin D (1:300)

  • Use Alexa 488/594-labeled secondary antibodies (1:200)

  • Mount with media containing DAPI for nuclear counterstaining

• Interpretation:

  • CBLN4 shows both cytoplasmic and secreted patterns

  • As a secreted protein, CBLN4 should show vesicular staining pattern

  • Verify extracellular localization with non-permeabilized immunostaining

How can CBLN4 antibodies be employed to investigate neurological disease mechanisms?

CBLN4 has emerging roles in neurological conditions:

• Synaptopathies:

  • Use CBLN4 antibodies to assess alterations in expression in models of:

    • Autism spectrum disorders (cerebellar pathology)

    • Schizophrenia (netrin/DCC pathway dysregulation)

  • Compare CBLN4 distribution between patient and control samples

• Cerebellar disorders:

  • CBLN family members show altered expression in:

    • Olivopontocerebellar atrophy (OPCA)

    • Shy-Drager syndrome

  • Quantitative IHC and WB analysis can measure CBLN4 changes in these conditions

• Developmental disorders:

  • CBLN4's role in synapse formation suggests involvement in neurodevelopmental conditions

  • Study temporal expression patterns during critical developmental windows

  • Correlate CBLN4 expression with synaptic marker changes

What experimental approaches best evaluate CBLN4 interactions with other cerebellin family proteins?

To characterize CBLN family interactions:

• Co-expression systems:

  • Transfect HEK293T cells with HA-tagged CBLN4 and FLAG-tagged CBLN1/2/3

  • Measure secretion efficiency of each protein alone versus in combination

  • CBLN4 can enable ER export and secretion of CBLN3, which cannot form homomeric complexes

• Structural analysis:

  • Analyze complex formation using biochemical approaches:

    • Size exclusion chromatography to separate different complex sizes

    • Blue native PAGE to preserve native complexes

    • Mass spectrometry to determine precise complex composition

• Functional readouts:

  • Compare binding properties of homomeric versus heteromeric complexes:

    • Complexes containing both CBLN1 and CBLN4 show altered receptor affinities

    • Use solid-phase binding assays with purified receptors (neurexins, DCC)

    • Measure functional outcomes in cell-based assays

What are the key experimental considerations when using CBLN4 antibodies to study its receptor interactions?

For studying CBLN4-receptor interactions:

• Binding assay design:

  • Use recombinant HA-CBLN4 in binding experiments

  • Pre-incubate DCC-expressing cells with netrin-1 (1 μg/ml) as a competition control

  • Include BSA (50 μg/ml) as a negative control

  • Analyze binding by cell-based ELISA or flow cytometry

• Receptor specificity analysis:

  • Unlike CBLN1/2, CBLN4 binds selectively to the netrin receptor DCC

  • Use parallel assays with CBLN1, CBLN2, and CBLN4 to demonstrate specificity

  • Verification requires showing netrin-displaceable binding

  • Consider other potential receptors: Igdcc4, Cntn3, Neo1

• Functional consequences:

  • Investigate whether CBLN4 modulates netrin-DCC signaling

  • Design experiments comparing netrin alone versus netrin+CBLN4

  • Measure established DCC-dependent outcomes (axon guidance, synaptic plasticity)

  • Use CBLN4-null mice tissues for validation studies